✦ LIBER ✦

Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer

✍ Scribed by Mark Garzotto; Anne Myrthue; Celestia S. Higano; Tomasz M. Beer

Book ID: 116955898
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 111 KB
Volume: 24
Category: Article
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2005.11.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant therapy for high-risk locali

Neoadjuvant therapy for high-risk localized prostate cancer

✍ Evan Y. Yu; William K. Oh 📂 Article 📅 2003 🏛 Current Science Inc. 🌐 English ⚖ 365 KB

Neoadjuvant and adjuvant chemotherapy fo

Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer

✍ Mari Nakabayashi; William K. Oh 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 236 KB

Neoadjuvant docetaxel and estramustine c

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer

✍ Maha Hussain; David C Smith; Basil F El-Rayes; Wei Du; Ulka Vaishampayan; Joseph 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Phase 1/2 study of preoperative docetaxe

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer

✍ Mark Garzotto; Celestia S. Higano; Catherine O'Brien; Brooks L. S. Rademacher; N 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

Neoadjuvant docetaxel followed by radica

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report

✍ William K Oh; Daniel J George; Donald S Kaufman; Keri Moss; Matthew R Smith; Jer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 569 KB

Neoadjuvant docetaxel treatment for loca

Neoadjuvant docetaxel treatment for locally advanced prostate cancer : A clinicopathologic study

✍ Cristina Magi-Galluzzi; Ming Zhou; Alwyn M. Reuther; Robert Dreicer; Eric A. Kle 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

## Abstract ## BACKGROUND. The objective of the current study was to determine the histologic and molecular changes that occurred in patients with high‐risk, localized prostate cancer (PCa) after neoadjuvant docetaxel chemotherapy. ## METHODS. Patients who had locally advanced PCa (serum preoper